HLF-positive B cell acute lymphoblastic leukemia (B-ALL) sits among the most aggressive blood cancers seen in children. The ...

Myeloma delivery constraints are dominated by CAR T infrastructure and onboarding, while bispecifics are more ...

AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral ...

Yatiri used its AI-based proteomics and functional testing platform to identify a biomarker profile for best responders to denfivontinib.

Yatiri Bio, Inc., a leader in AI-driven precision medicine, today announced it has entered into an exclusive global option to ...

Patients testing positive for NPM1 MRD pre-alloHCT have significantly increased rates of relapse, reduced overall survival ...

ASH convened a multidisciplinary panel to develop evidence-based guidelines for the treatment of newly diagnosed acute myeloid leukemia in older adults, focusing on balancing treatment efficacy with ...

Glenn Czech, a devoted medical coder and bowler, is remembered for his kindness and faith. Friends and family will gather for his memorial service on March 25th in Sauk Rapids.

A 49-year-old man with a history of acute myeloid leukemia who received an allogeneic bone marrow transplant 2 weeks prior developed a widespread rash. On physical examination, fever of 38.5°C (101.3 ...

PARADIGM data suggest azacitidine plus venetoclax improves AML event-free survival vs 7+3 with less toxicity; survival looks ...

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today ...